AUPH News and Press, Aurinia Pharmaceuticals Inc From 06/20/19

To ensure your vote is counted, shareholders are encouraged to vote their GREEN Proxy today in advance of the voting deadline of Friday, June 21, 2019 at 5:00 p.m. (MST) Questions? Need help? Contact call Gryphon Advisors Inc. at: 1-833-266-0365 or at inquiries@gryphonadvisors.ca . ...

ISS and Glass Lewis Recommend Aurinia Shareholders Not Support ILJIN’s Nominees Highlight Aurinia’s Strong Track Record of Shareholder Value Creation Note ILJIN has Failed to Make a Compelling Case for Change Leading independent proxy advisory firms Institution...

Details Aurinia’s Underperformance Resulting from Poor Governance Practices, Bloated Compensation, CEO Turnover and Conflicts of Interest under Incumbent Board Shareholders Urged to Vote Their GREEN Proxy or GREEN VIF to Strengthen Board with Three New, Highly Qualified Independent...

Shareholders Urged to Vote Their GREEN Proxy or GREEN VIF to Strengthen Board with Three New, Highly Qualified Independent Nominees ILJIN SNT Co., Ltd. (“ ILJIN ”) today sent a letter to shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (“ Aurinia ...

Highlights the Company’s strong progress, advancement of voclosporin, and value creation for all shareholders Notes recent Board refreshment, deep expertise in drug commercialization Believes ILJIN has offered no plan for value creation Corrects ILJIN’s mis...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the following upcoming investor conferences: Jefferies Healthcare Conference on Friday, June 7, 2...

Three Independent Directors Nominated to Strengthen Board, Remove Conflicts and Return Control of the Company to Shareholders Commercial Potential of Voclosporin is Tremendous, But Not Reflected in the Company’s Share Price Under Current Leadership Current Group of Hand-Picked a...

- Special Committee of the Board and Management urges you to vote your shares using the YELLOW proxy - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), today filed its Notice of Meeting and Management Information Cir...

Market Assessment ChemoCentryx ( CCXI ) is a clinical-stage small market cap ($683M) biopharma developing innovative therapeutics predominantly for kidney diseases. Its scientific forte is chemokine biology. This is not surprising since Thomas Schall, PhD, the founder of ChemoCentryx, is a...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET...